Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa

被引：9

作者：

Mosam, A ^{[1
]}

Cassol, E

Page, T

Bodasing, U

Cassol, S

Dawood, H

Friedland, GH

Scadden, DT

Aboobaker, J

Jordaan, JP

Lalloo, UG

Esterhuizen, TM

Coovadia, HM

机构：

[1] Africa Ctr Hlth & Populat Studies, Dept Dermatol, Durban, South Africa

[2] Africa Ctr Hlth & Populat Studies, Dept Mol Virol & Bioinformat, Durban, South Africa

[3] Yale Univ, Sch Med, Ctr HIV AIDS Networking, New Haven, CT USA

[4] Yale Univ, Sch Med, Dept Infect Dis, New Haven, CT USA

[5] Yale Univ, Sch Med, AIDS Programme, New Haven, CT USA

[6] Harvard Univ, Sch Med, MGH Canc Ctr, Dept Haematol Malignancies, Cambridge, MA 02138 USA

[7] Univ KwaZulu, Nelson R Mandela Sch Med, Fac Hlth Sci, Dept Radiotherapy & Oncol, Natal, South Africa

[8] Univ KwaZulu, Nelson R Mandela Sch Med, Fac Hlth Sci, Med Bioeth Unit, Natal, South Africa

[9] Univ KwaZulu, Nelson R Mandela Sch Med, Fac Hlth Sci, Victor Diatz Chair HIV AIDS Res, Natal, South Africa

来源：

AIDS | 2005年 / 19卷 / 04期

关键词：

D O I：

10.1097/01.aids.0000161775.36652.85

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Generic antiretroviral drugs are pivotal in the implementation of WHO's '3 by 5' programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74% achieved an undetectable viral load of < 50 copies/ml, 86% achieved < 400 copies/ml, and a 3.1 log(10) decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy.

引用

页码：441 / 443

页数：3

共 50 条

[1] Epidemiology of Kaposi's sarcoma in sub-Saharan Africa
Motlhale, Melitah
Sitas, Freddy
Bradshaw, Debbie
Chen, Wenlong Carl
Singini, Mwiza Gideon
de Villiers, Chantal Babb
Lewis, Cathryn M.
Muchengeti, Mazvita
Waterboer, Tim
Mathew, Christopher G.
Newton, Robert
Singh, Elvira
CANCER EPIDEMIOLOGY, 2022, 78
[2] Kaposi's sarcoma in sub-Saharan Africa: a current perspective
Mosam, A.
Aboobaker, J.
Shaik, F.
CURRENT OPINION IN INFECTIOUS DISEASES, 2010, 23 (02) : 119 - 123
[3] AIDS-associated Kaposi's sarcoma
Kroll, MH
Shandera, WX
HOSPITAL PRACTICE, 1998, 33 (04): : 85 - +
[4] Transmission of Kaposi sarcoma-associated herpesvirus in sub-Saharan Africa
Mbulaiteye, Sam M.
Goedert, James J.
AIDS, 2008, 22 (04) : 535 - 537
[5] Paclitaxel for AIDS-associated Kaposi's sarcoma
Dhillon, T
Stebbing, J
Bower, M
EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (02) : 215 - 219
[6] The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma
Dupin, N
De Cervens, VR
Gorin, I
Calvez, V
Pessis, E
Grandadam, M
Rabian, C
Viard, JP
Huraux, JM
Escande, JP
BRITISH JOURNAL OF DERMATOLOGY, 1999, 140 (05) : 875 - 881
[7] AIDS-Associated Kaposi Sarcoma
Clark, Kevin R.
RADIOLOGIC TECHNOLOGY, 2023, 94 (06) : 464 - 467
[8] Extensive AIDS-associated Kaposi's sarcoma
Medina-Pinon, Isai
Wah-Suarez, Martin
Arturo Acosta-Calderon, Luis
Ramos-Jimenez, Javier
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 67 : 137 - 138
[9] Foscarnet and AIDS-associated Kaposi's sarcoma
Cordero, E
LopezCortes, LF
Viciana, P
Alarcon, A
Pachon, J
AIDS, 1997, 11 (14) : 1787 - 1788
[10] LAMP-enabled diagnosis of Kaposi's sarcoma for sub-Saharan Africa
McCloskey, Duncan
Semeere, Aggrey
Ayanga, Racheal
Laker-Oketta, Miriam
Lukande, Robert
Semakadde, Matthew
Kanyesigye, Micheal
Wenger, Megan
LeBoit, Philip
McCalmont, Timothy
Maurer, Toby
Gardner, Andrea
Boza, Juan
Cesarman, Ethel
Martin, Jeffrey
Erickson, David
SCIENCE ADVANCES, 2023, 9 (02)

← 1 2 3 4 5 →